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INTRODUCTION 
 
 
Pemphigus Vulgaris is a chronic autoimmune blistering disease of skin 
and mucous membrane.  Prior to the advent of corticosteroids, the majority of 
patients with Pemphigus Vulgaris died from overwhelming sepsis.  After 
introduction of systemic steroids, survival has improved dramatically.  However 
mortality and morbidity is still very high due to steroid related side effects.  
Adjuvants like Azathioprine, Methotrexate and Cyclophosphamide were added 
to the treatment of Pemphigus Vulgaris to reduce the high morbidity associated 
with long term use of oral steroids. 
   Pulse therapy refers to the administration of a drug intermittently to 
accelerate the therapeutic efficacy.  Pulse therapy using a combination of 
Corticosteroids and Cyclophosphamide is reported to reduce the mortality and 
morbidity of Pemphigus Vulgaris.  This was introduced by Pasricha et al and by 
Kanwar.    
 
 
 
PULSE THERAPY 
Pulse therapy means administration of a drug or drugs intermittently to 
accelerate the therapeutic efficacy and reduce the possibility of adverse effects 
related to the daily dosage schedule. In case of pulse steroid therapy, large (supra 
pharmacological) doses are used to accelerate the therapeutic efficacy without 
much side effects. 
  The first reported use of pulse administration of corticosteroids is 
attributed to Kountz and Cohn1 who used it successfully to prevent renal graft 
rejection. Subsequently, pulse doses of corticosteroids were used for several 
other diseases such as Lupus nephritis2, Rheumatoid arthritis3 and Pyoderma 
gangrenosum4, but usually to deal with emergency situations only and not as a 
preferred method of treatment.  Methyl prednisolone was the commonest drug 
used, in a dose of 1gm per dose commonly for 3-5 days as an infusion. 
Dexamethasone Cyclophosphamide Pulse therapy for pemphigus was first 
introduced by Pasricha at AIIMS, New Delhi in 19865. 
THE STANDARD REGIMEN:                  
  In its present form6, it consists of giving 100 mg of dexamethasone 
dissolved in 500ml of 5% glucose as a slow intravenous drip over 2 hours 
repeated on 3 consecutive days.  On the second day, the patient is also given 
500mg of Inj. Cyclophosphamide in 500ml of 5% Dextrose.  This constitutes one 
DCP. Such DCPs are repeated at exactly 28 day intervals counted from the first 
day of the pulse.  In between the DCPs the patient receives only 50 mg of 
Cyclophosphamide orally per day.  The DCP regimen is administered in four 
phases. 
During the first few months (PHASE 1) the patient may continue develop 
recurrences of clinical lesions in between the DCPs.  This phase is continued 
till the patient attains complete remission.  Remission is defined as complete 
healing of the existing lesions and absence of new lesions. 
During PHASE 2, the patient remains completely alright clinically but 
receives 9 more DCPs at exactly 28 day cycles along with 50mg 
Cyclophosphamide orally. 
 During PHASE 3, the DCPs are stopped and the patient receives only 
50mg Cyclophosphamide orally per day for the next 9 months.                   
After this, the treatment for pemphigus completely withdrawn and the patient is 
followed up for the next 10 years to look for a relapse if any (PHASE 4). 
                   During the early days of DCP, 6 DCPs were given during phase 2 
and the duration of phase 3 was 12 months. 
 
 OBJECTIVES OF DCP THERAPY:  
1) To achieve a faster response and greater efficacy. 
2) To reduce the need for long-term use of systemic steroids. 
3) To achieve a steroid sparing effect. 
 
CORTICOSTEROIDS: 
          Corticosteroids  was first introduced in dermatology by Marion 
Sulzberger. 
Pharmacological considerations:             
They are - Anti-inflammatory                          
                - Immunosuppressive                            
                - Antiproliferative and                                
                - Vaso constrictive. 
 
 
 
Biology 
The major naturally occurring Glucocorticoid is Cortisol.  It is synthesized 
from cholesterol by the adrenal cortex.  Normally less than 5% of the circulating 
Cortisol is unbound; this free cortisol is the active therapeutic molecule.  
 The remainder is inactive because it is bound to Cortisol Binding 
Globulin (CBG, also called Transcortin.) 95% or to albumin 5%.  The daily 
secretion of cortisol ranges between 10 and 20mg  with a diurnal  peak at  
8 A.M 7. 
Cortisol has a plasma half-life of 90 minutes.  Primarily the liver 
metabolizes it, although it exerts its hormonal effects on virtually every tissue in 
the body. The metabolites are excreted by the liver and the Kidney. 
Mode of action:               
1) Glucocorticoids act  by  binding  to  the  intracellular Glucocorticoid  
    receptor leading to dimer formation and subsequent binding to specific     
DNA  regulatory sequences known as GLUCOCORTICOID RESPONSE 
ELEMENTS (GREs).  This interaction leads to upregulation or down 
regulation of specific genes that encode for  proteins, such as many cytokines 
and adhesion molecules. 
2) Glucocorticoids can modulate transcription in a hormone dependent manner, 
not through direct binding to GREs, but through interference with the activity 
of other transcription factors such as AP-1, NF-κB, Immunophilin and 
CREB.   These factors are involved in the inducible regulation of many 
genes, several of which relate to the immune cell function and production of 
inflammatory mediators8.                                                          In the case of 
NF-κB, Glucocorticoids can also block nuclear translocation and  DNA 
binding of NF-κB through induction of IκB alpha protein and cytoplasmic 
trapping of NF-κB9.   
3)There are also post transcriptional effects of Glucocorticoids which include 
effects on RNA translation, protein synthesis and secretion. End result of all 
these many effects is that Glucocorticoids inhibit the access of inflammatory 
cells to tissue, interfere with function of fibroblasts and endothelial calls and 
suppress production and effects of humoral factors. 
4) Glucocorticoids increase the synthesis of other important molecules such as 
Annexins 1 and 2.  Annexins reduce the Phospholipase activity which reduces 
the release of arachidonic acid from membrane phospholipids10,11 limiting the 
formation of Prostaglandins and Leucotrienes12,13. 
5) Glucocorticoids profoundly affect the replication and movements of cells.  
They induce monocytopenia, eosinopenia and lymphocytopenia and have a 
greater effect on T cells than on B cells14.                          
6) Glucocorticoids affect cell activation, proliferation and differentiation.  They 
modulate the levels of mediators of inflammation and immune reaction as 
seen with the inhibition of IL-1, IL- 2, IL- 6 and TNF synthesis15,16. 
7) They suppress monocyte and lymphocyte function more than 
polymorphonuclear leukocyte functions. 
 In Pulse therapy : Glucocorticoids exerts additional effects in addition to the 
above:  
1)Glucocorticoids exert their effects by non genomic mechanism such as 
membrane bound receptors or physicochemical interaction with cellular 
membranes.   
2) They also cause apoptosis of inflammatory cells, especially peripheral blood 
CD4+ T- Lymphocytes. 
 
 
 
PHARMACOLOGY: 
Basic steroid structure:                                                              
 
 
               
 
 
Classification of steroids according to duration of action 
                                                Duration of action             Plasma half-life 
                                                      (hours)                                  (hours) 
Short  acting: 
Hydrocortisone                                    8-12                                    90   
Cortisone                                              8-12                                   30 
Intermediate acting: 
Prednisone                                            24-36                                  60 
Prednisolone                                         24-36                                 200 
Methyl Prednisolone                             24-36                                 180 
Triamcinolone                                       24-36                                 300 
 
1
2
3
4 6
5
9
11
17
18
O
Long acting: 
Dexamethasone                                      36-54                                200 
 
 
PHARMACOKINETICS OF CORTICOSTEROID PULSE:  
              Conventionally, methyl prednisolone has been the agent used in 
corticosteroid pulse therapy.  However, in India various workers have used 
dexamethasone with significant success.  This is particularly due to the easy 
affordability and accessibility of the drug to the patients.  The pharmacokinetics 
is complex.  There is a rapid peak with a subsequent serum half life of 3 hours.  
A very large proportion of IV bolus rapidly enters the gut, manifests in part by 
the development of metallic taste in the mouth, and this reenters the venous 
space via the splanchnic circulation causing a secondary peak in the serum level.  
Cortisol levels do drop initially but reverts to normal levels within 24-48 hours 
after infusions17.  After prolonged use of IV pulse doses of steroids in children, 
morning and evening levels of serum Cortisol and ACTH were estimated to be 
normal after 3 months to 5 years of weekly boluses18.  Studies on bone 
metaboism have showed decreased absorbtion of calcium from the gut and its 
renal excretion, increased parathyroid hormone and 
1,25dihydroxycholecalciferol, and decreased bone resorption and formation 
immediately after single boluses19, but no net change except for a slight decrease 
in hydroxyproline excretion after 3 boluses given on alternate days20.  This was 
confirmed by a study of deoxypyridinoline excretion as a measure of bone 
collagen degradation. 
          Very high levels of corticosteroids obtained by pulse therapy exert              
additional effects that are not just a result of more number of drug molecules 
multiplying the same.  
IMMUNOLOGICAL ALTERATION AND ANTI 
INFLAMMATORY ACTIVITY OF PULSE STEROID:   There is 
an acute drop in the circulating T and B-cells 5 hours after infusion of pulse 
steroid which reverts to normal within 24 hours.  However Leu-3a subsets of T-
helper cells reach normal levels by 48 hours21.             
There is no significant rise in the uric acid excretion.  Perhaps these doses 
of Corticosteroids do not kill a significant proportion of cells; rather it causes 
transient redistribution between the circulation and lymphoid organs.  Normal 
immune responses do not appear to be affected by large pulses. Fan et al22 found 
no change in the circulating immunoglobulin, primary or secondary antibody 
responses or delayed hypersensitivity skin reactions.  Delayed hypersensitivity 
reactions to antigens to which the children had been exposed earlier and primary 
response to pneumcococcal vaccine. 
Pulse Corticosteroids is used mostly to ameliorate the systemic 
inflammatory response syndrome, which is thought to result from activation of 
the complement system by bubble oxygenating pumps.  It has been seen that 
those who receive pulse steroids have low circulating levels of complement 
activation fragments and pro-inflammatory cytokines IL-1, IL-6, IL-8, and TNF-
ά and higher levels of anti-inflammatory IL-4 and IL-10 . 
CYCLOPHOSPHAMIDE                   
An alkylating agent was first synthesized as a derivate of nitrogen 
mustard.  It is used as an immunosuppressant in the treatment of various 
autoimmune disorders. 
Pharmacokinetics:              
Oral Bioavailability is 74%.  Peak Plasma levels occur at 1 hour.  It is 
widely distributed throughout the body including cerebrospinal fluid.  The half 
life of the drug ranges from 2-10 hours.  It is decreased in children and increased 
in cirrhosis.  The drug is only 13% protein bound but its metabolites are 
approximately 50% protein bound in plasma.              
Cyclophosphamide is primarily metabolized by the liver.  It is a 
PRODRUG which gets activated in the liver by conversion through cytochrome 
P450 to 4-hydroxy cyclophosphamide.  Its immunosuppressive properties are 
due to the metabolite Chloracetaldehyde produced after side chain oxidation of 
Cyclophosphamide23. 
Hepatic metabolism is the principal route of elimination of 
Cyclophosphamide.  Seventy percent of the drug is excreted in the urine as 
inactive compounds.  Because the clearance of the active metabolites occurs by 
spontaneous degradation rather than renal excretion, renal failure does not 
influence toxicity directly.  There is no need for dosage adjustment in the 
presence of either renal or hepatic failure24. 
MODE OF ACTION25: 
Cyclophosphamide is an alkylating agent.  It has the ability to form strong   
electrophiles that form covalent linkages to electron rich groups of DNA. The 
active metabolite is phosphoramide mustard, which undergoes cyclization to the 
reactive aziridium intermediate, which in turn alkalizes the DNA.  The result is 
irreparable damage to the DNA and subsequent apoptosis of the cell. 
                Cyclophosphamide although highly toxic to the rapidly dividing cells 
is different from several other cytotoxic agents in that it is toxic to the cells in all 
phases of   the cell cycle26. 
Cyclophosphamide is referred to as CELL CYCLE specific rather than a 
phase specific antineoplastic agent.  It is the cell cycle specific characteristic of 
Cyclophosphamide that is responsible for its cytotoxic effect on immune cells.  It 
depresses B cell function more than T cell function.  Suppressor T cells appear to 
be more affected than helper T cells. 
ADVERSE EFFECTS: 
Hematological toxicity:         
Manifests as myelosuppression, which is the primary, dose limiting side 
effect. Thrombocytopenia occurs less frequently.  
Leukocyte count nadir occurs 8-12 days after therapy is initiated. 
 Gonodal damage: 
          Azospermia and premature ovarian failure is a well defined side effect of 
Cyclophosphamide.  The characteristic finding in male gonadal toxicity is 
testicular germ cell depletion, whereas in females it causes disappearance of 
primordial ovarian follicles. 
 
Urological damage: 
           Cyclophosphamide causes increased frequency, dysuria, urgency, 
microscopic haematuria, hemorrhagic cystitis, fibrosis of bladder, and bladder 
necrosis. 
      One of the metabolic products, ACROLEIN is thought to be the cause of 
hemorrhagic cystitis.  MESNA binds and inactivates acrolein, allowing for 
elimination of inactivated compounds in urine.  Ensuring both adequate 
hydration and administration of mesna during treatment has been reported to 
decrease markedly the incidence of bladder complications. 
Carcinogenesis: 
            Cyclophosphamide is linked to squamous cell carcinoma of bladder, 
urinary tract, and carcinoma of the renal pelvis and ureter. 
INDICATIONS AND CONTRAINDICATIONS OF DCP 
THERAPY IN IMMUNOBULLOUS DISEASE27:  
               Since the pulse regimen virtually cures every pemphigus patient for the 
rest of his life and there are almost no side effects, all Pemphigus patients 
deserve to be treated with this regimen irrespective of whether they are having 
severe or mild disease. Even those patients who are in clinical remission but 
have to take maintenance doses of corticosteroids or immunosuppressive drugs 
can be made to give up maintenance doses by administering them a course of 
DCP regimen. 
1) DCP therapy can be given to patients of all ages but the doses have to be 
reduced to half for children below the age of 12 years 
2) It can also be given to patients with Diabetes mellitus, Hypertension,  
Hyperacidity, Osteoporosis, Tuberculosis etc., but each patient must receive 
additional appropriate treatment for the concomitant disease whenever necessary.                   
3) Diabetic patients need to be given 10 units of soluble Insulin for every 500ml 
bottle of 5% glucose dissolved in the same drip in addition to the routine 
treatment for diabetes.                   
4) In Hypertensive patients, BP must be monitored   regularly and the treatment 
for hypertension adjusted if necessary.   
5) Patients having hyperacidity can continue to take antacids or H2 blockers as 
required                        
6) Even those having active tuberculosis can continue the pulse therapy along 
with the anti tubercular treatment.  
7) Viral warts and molluscum contagiosum can also be treated concomitantly 
along with the pulse therapy. 
8) If a patient has severely infected lesions or there is a serious infection 
elsewhere, the start of the pulse therapy can be delayed for a week or two till the 
infection has been brought under control. 
9)    Similarly patients having herpes simplex, herpes zoster or even chicken pox 
can be given concomitant treatment with acyclovir and the pulse therapy can be 
continued except under exceptional circumstances when the viral infection is 
very severe.                       
The absolute contra indications are 
1) Pregnancy 
2) Lactation 
3) Severe cardiac or respiratory compromise 
In a pregnant lady, the pulse therapy is only to be postponed till the  
patient has delivered the baby and stopped feeding the child.  Till that time the 
patient is to be maintained on a regular dose of corticosteroid just sufficient to 
keep the disease under control.                                   
           Patients who are unmarried or those who have not yet completed their 
family and want to have more children, have to be given dexamethasone pulses 
and not DCPs.  Cyclophosphamide in the pulses has to be avoided because it can 
lead to amenorrhea or azospermia in a significant proportion of patients.  The 
low dose daily Cyclophosphamide can be continued.     
   
MODIFICATIONS TO STANDARD DCP REGIMEN28: 
a) All hospitalized patients were treated for intercurrent infections and given 
conventional steroid therapy to control the activity of Pemphigus.  The first pulse 
was initiated when the secondary infection was fully controlled and existing 
lesions were reduced in number.  
b) When Cyclophosphamide 500mg was added to the drip on the second day of 
DCP, it was followed by an additional 5% dextrose of 500ml, to prevent the 
urinary complications of Cyclophosphamide. 
c) As part of the protocol, the following supportive drugs were given to all 
patients: oral calcium 500 mg daily, during the first three phases, and  
Inj. Vitamin D 3lakh units once a month during the first two phases. 
d) Patients with oral lesions were encouraged to clean the oral cavity with 
regular brushing of the teeth.  They were advised to massage a topical 
corticosteroid gel on the oral ulcers 3-4 times a day especially after meals and 
given ketoconazole 200mg per day orally and 500mg Ciprofloxacin or 
Cefadroxil twice daily.  This change leads to the healing of oral lesions with in 
2-3 months. 
e) Earlier patients received only monthly pulses of corticosteroids, but with the 
observation many patients developed some degree of recurrence of lesions 
between the pulses in the early stages of therapy, daily corticosteroids were 
added in the first few months29. 
f) Patients with extensive active disease were also given interval pulses of 
dexamethasone29  
FACTORS CONTRIBUTING TO THE SUCCESS OF DCP 
THERAPY30: 
1) The choice of the drug: Conventionally methyl prednisolone was the drug 
most commonly used in corticosteroid pulse therapy.  The choice of 
dexamethasone made the treatment more affordable and accessible to the 
patients 1000 mg of methyl prednisolone is equivalent to 138 mg of 
dexamethasone. However a dose of 1000mg of methyl prednisolone is as 
arbitrary as 100mg of dexamethasone and in the absence of evidence that 
136mg of dexamethasone is more effective, nearly all centers continue to use 
100mg boluses. 
 2) In the early days, DCP was administered in the ICU under continues 
cardiac monitoring.  It is now given as a routine infusion often in a day care 
or a OPD setting. 
3) The treatment has evolved in response to the observations of the results of 
the treatment in patients who were receiving this form of therapy. 
a)Initially only dexamethasone pulses were used.  Cyclophosphamide 
boluses were added because relapses were frequent with dexamethasone 
alone. 
b) Insistence on the 28-day cycles for pulses is based on the observation 
that relapses are commoner in those who took pulses irregularly. 
c)  Current recommendation of administering 9 pulses during phase 2 was 
arrived at by observing that relapse rate was commoner in patients 
receiving 6 pulses during phase 2. 
 
ADVANTAGES OF DCP: 
1) Better control of the disease to the point of presumptive cure. 
2)  Near absence of steroid side effects. 
a) Studies31 show that there is almost no risk of developing Diabetes, 
Hypertension, Peptic ulceration, Osteoporosis, striae, acne, hirsuitism, 
unless the patient was receiving or had received daily doses of steroids. 
b) Does not lead to an increase in body weight unless the patient was 
receiving daily Corticosteroids and if the patient had already developed 
cushingoid obesity due to previous treatment, the body weight and 
appearance wound actually return to normal during the pulse therapy. 
c) Studies31 have found no significant effect of pulse therapy on bone 
mineral density or metabolism. 
d) The HPA axis was found to rapidly return to normal after pulse therapy 
than after daily doses of steroids. 
3) Reduced length of stay in the hospital. 
 ADVERSE EFFECTS OF DCP THERAPY: 
              The adverse effects of pulse therapy can be due to the constituents of 
the pulse or due to the pulse itself and are subdivided as follows: 
DUE TO CORTICOSTEROID32: 
1) Viral, bacteria and fungal infections 
2) Hyperacidity 
3) Diabetes mellitus 
4) Hypertension 
5) Demineralization of bone / Avascular necrosis 
6) Spontaneous rupture of the Achilles tendon33 
DUE TO CYCLOPHOSPHAMIDE: 
1) Leucopenia 
2) Thrombocytopenia 
3)  Diffuse loss of hair 
4) Diffuse Hyper-pigmentation of skin and hyperpigmented bands in nails 
5) Hemorrhagic cystitis 
6) Gonadal Damage 
7) Carcinogenesis 
DUE TO PULSE34: 
1) Hiccups35                                              2) Facial flushing36 
3 Weakness                                         4)Metallictaste                         
5)Muscle and bone pain   6)Generalisedswelling 
7) Diarrhoea     8) GI bleeding   
9) Headache                                            10) Loss of taste  
11) Menstrual irregularities                     12) Hair Loss 
13) Sleep Disturbances                           14) Palpitation 
15) Hypotension                                      16)Arrhythmias 
17)Congestive cardiac failure                  18) Pulmonary oedema 
19)Ischemic Heart Disease                       20)Sudden Death 
21) Acute Psychosis                                 22) Seizure 
23)Anaphylaxis 
 
 
Flushing: The high dose of Glucocorticoids produces vasodilation that is 
reflected as flushing over areas like face, palms and soles37. 
Palpitations: Glucocorticoids exert a positive inotropic effect over the heart and 
increase epinephrine synthesis38. 
Weakness: Hypothalamic Pituitary Adrenal axis suppression39 produced by 
dexamethasone therapy at the level of pituitary persists for about 7-10 days40, 
and may result in reduced production of all hormones including ACTH.  Such 
hormonal dysregulation might be responsible for the malaise. 
Menstrual irregularities: Gonadotropin dysregulation because of pituitary 
suppression may be causing the menstrual irregularities. 
Psychosis: Corticosteroids influence the physiology of the central nervous 
system in various ways.  Glucocorticoid receptors are present at sites like 
cerebellum, hypothalamus and dentate gyrus, and most importantly the 
hippocampus41- an important channel receiving the sensory inputs controlling the 
behaviour.  Suprapharmacological dose of the glucocorticoids, particularly 
dexamethasone has a special affinity for type 2 receptors that potentiate the 
damage to hippocampal cells produced by kainic acid42, thereby suppressing the 
hippocampal excitability and producing various behavioural alterations. 
 
Bad taste/ Diarrhea: Coincides with the pulses and responds to a 7 day course 
of Ciprofloxacin for 2-3 consecutive days. All the side effects related to 
corticosteroids were reported to be much less in cases of pulse therapy.  Pituitary 
adrenal axis is suppressed in about half of the patients on pulse therapy.  
However, it reverts to normal in a few days and clinically the patients remain 
normal during the treatment and subsequent follow up. 
 Hair loss: Could be due to either drug induced or stress related tetogen 
effluvium.  Dexamethasone influences the hormonal physiology of the hair 
follicle by inhibiting dihydro-testosterone whereas Cyclophosphamide has a  
direct cytotoxic effect on the hair follicle. 
Head ache : May be due to cerebral vasodilatation. 
Sleep disturbance: Glucocorticoids activate the CNS and decrease REM sleep43.  
Polyurea: This is due to the involvement of Atrial Naturetic Factor.  
Glucocorticoids increase the rate of transpcription of ANF in mRNA in 
cardiocytes44, stimulate ANF secretion45 and upregulate ANF receptors on 
endotheial cells. 
 
 
 
Acute Cardiovascular complications: 
           These are among the serious adverse effects. They are very rare and 
 typically occurred in patients with underlying kidney or heart disease.  
Electrolyte shifts and rapid rate of infusion were believed to underlie atleast 
some of the events. 
             ECG abnormalities can resolve with potassium infusion despite normal 
serum levels which suggests that electrolyte shifts may precipitate some of the 
adverse effects47.  Continuous cardiac monitoring is warranted only in patients 
with underlying kidney or heart disease and daily and post infusion electrolyte 
monitoring is indicated in these patients.         
            A slow rate of infusion, usually over 2-3 hours is recommended ,because 
a faster rate has been associated with a greater risk of arrhythmias, hypotension 
and electrolyte shifts. 
Infections: The risk of increased pyogenic infections on the skin and candidiasis 
in the mouth persisted only as long as the patients had ulcers on the skin and oral 
cavity and therefore vigorous treatment with systemic antibiotics and antifungal 
agents during this period was helpful. 
          Viral or dermatophyte infections should be treated on their own merit 
without interrupting pulse therapy regimen. 
All the side effects related to corticosteroids were reported to be much less 
in cases of pulse therapy.  Pituitary adrenal axis is suppressed in about half of the 
patients on pulse therapy.  However, it reverts to normal in a few days and 
clinically the patients remain normal during the treatment and subsequent follow 
up. 
Monitoring of patients on Pulse therapy:  
Before each pulse: Complete blood count, urine analysis, electrocardiogram, 
blood sugar, Renal Function Tests, Liver Function Tests, Serum Electrolytes. 
After each pulse: Urine analysis, Serum electrolytes. 
Chest x ray has to be done after every 6 pulses.     
INDICATIONS FOR DCP PULSE THERAPY: 
   Although pulse therapy has been advocated for various cutaneous and 
systemic diseases, it can be categorized under 3 headings: 
1) Established dermatological indications: Diseases where the therapy has 
been extensively used and there are a good number of studies regarding 
their efficacy. 
2) Dermatological diseases with limited experience: Conditions where 
there are a few anecdotal reports of the efficacy of pulse therapy. 
3) Systemic disorders 
 
ESTABLISHED DERMATOLOGICAL INDICATIONS: 
1) Pemphigus vulgaris47-53 
2) Bullous pemphigoid53 
3) Localized scleroderma54 
4) Pyoderma gangrenosum55-56 
5) Reiter’s disease 
 
DERMATOLOGICAL DISEASES WITH LIMITED 
EXPERIENCE: 
1) Extensive alopecia areata/ alopecia universalis57-58    
2) Extensive lichen planus59 
3) Prurigo nodularis60 
4) Generalized morphoea 
5) DLE61 
6) Extensive vitiligo 
7) Allergic vasculitis 
8) Disseminated porokeratosis62 
9) Dariers disease 
10) Hailey Hailey disease 
11) Multiple Keloids 
12) Post burn contractures 
13) Sarcoidosis 
14) Multicentric reticulohistiocytosis63 
15) Peyronies disease 
16) Urticarial vasculitis64 
17) TEN65 
18) SJS 
SYSTEMIC DISORDERS 
1) Systemic sclerosis66-67 
2) SLE/renal lupus/lupus meningitis68 
3) Rheumatoid arthritis 
4) Graves disease with ophthalmopathy69 
5) Kawasaki disease70 
6) IgA nephropathy71 
7) Moderate to severe ulcerative colitis72 
OTHER PULSE THERAPIES FOR PEMPHIGUS 
1) Dexamethasone Azathioprine Pulse (DAP): 
           Here cyclophosphamide is replaced with 50mg of Azathioprine daily 
during the first 3 phases.  No bolus dose of Azathioprine is given during the 
pulse.  This regimen is a viable option for patients who are unmarried or have 
not completed their family. 
 
2) Dexamethasone Methotrexate Pulse (DMP): 
           Here Cyclophosphamide is replaced by 7.5mg of Methotrexate (three 
doses of Methotrexate 2.5mg at 12hourly intervals) weekly given orally during 
the first 3 phases of pulse therapy. 
  There are no reports of abnormal children fathered by men receiving 
Methotrexate therapy although the sperm motility may be abnormal during 
treatment. Methotrexate has no apparent effect on the outcome of pregnancies 
occurring after it is discontinued. 
DMP regimen can also be considered for patients who have not completed their 
family.          
4) Pulse Glucocorticoid therapy: 
Methyl prednisolone and dexamethasone are the glucocorticoids most 
frequently administered in the pulse regimen. 
Doses of each pulse are usually 10-20mg/kg body weight for methyl 
prednisolone and 2-5mg/kg body weight for dexamethasone.  Pulses are usually 
given daily for 3-5 days. 
6) Cyclophosphamide pulse therapy: 
        Cyclophosphamide 500mg was dissolved in 25ml of distilled water 
which was added to 500mg of 5% dextrose and given slowly intravenous for 
60 minutes.  
  It was followed by 500ml of normal saline.  Similar pulses were repeated 
monthly for 12 months and 2 monthly for further 6 pulses. 
Indications for cyclophosphamide pulse: 
1) Resistance to control with prednisolone 
2) Weight gain.  
3) Psychosis 
4) Aseptic necrosis of bone 
5) Severe hypertension 
6) Uncontrolled Diabetes                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEMPHIGUS 
 
The term ‘Pemphigus’ refers to a group of autoimmune blistering diseases 
of skin and mucous membranes that are characterized histologically by 
intraepidermal blisters due to acantholysis (ie. separation of epidermal cells from 
each other) and immunopathologically by in vivo bound and circulating IgG 
antibodies directed against the cell surface of the Keratinocytes 
Pemphigus is derived from the Greek word, Pemphix, meaning blister or 
bubble. 
TYPES OF PEMPHIGUS 
Pemphigus Vulgaris 
 Variant : Pemphigus Vegetans 
Pemphigus foliaceus 
 Variant : Pemphigus herpetiformis 
 Variant : Pemphigus erythematosus 
Induced Pemphigus 
Intercellular IgA Dermatosis 
Paraneoplastic Pemphigus  
 
 
 
PEMPHIGUS VULGARIS 
 Affects all races and both sexes. It is a disease of middle age but patients 
are younger at presentation in India than in western countries73 
INCIDENCE AND PREVALANCE : 
Pemphigus Vulgaris accounts for approximately 70% of all cases of 
Pemphigus. 
 It is the most common autoimmune blistering disease in eastern countries, 
such as India, Malaysia, China, Middle east74. 
The Jewish race, especially Ashkenazi Jews, have an increased 
susceptibility to Pemphigus Vulgaris75. Pemphigus is less common in the west. 
GENETICS : 
Predisposition is linked to genetic factors. Certain major 
histocompatibility complex (MHC) class II genotypes, in particular alleles of 
HLA – DRBI*04 and DRBI*14 subtypes are common in patients with 
Pemphigus vulgaris76. These alleles produce amino acid substitutions in HLA – 
DRB1 peptide binding sites, which may influence antigen presentation and 
recognition by T-cells. Susceptibility may also be determined by genes encoding 
immunoglobulins. 
 
 
ENVIRONMENTAL FACTORS : 
Viral  DNA (herpes simplex, Ebstein-Barr Virus, Human Herpes Viruses 6 
and 8) has been detected in some skin biopsies from Pemphigus patients77. 
Pemphigus has coexisted with HIV infection78. 
Dietery agents implicated in the causation of pemphigus vulgaris are 
Allium group (onion,garlic), shallots,tannins (certain fruits), radish,phenols 
(artificial sweetners,preservatives,colouring agents),mustard (thiocynates) 
PATHOGENESIS : 
Autoantibodies against the surface of Keratinocytes occur in Pemphigus. 
PEMPHIGUS VULGARIS ANTIGEN : 
 Also known as Desmoglein 3, is a desmosomal cadherin involved in 
mediating intercellular adhesion in the epidermis. The antibody binds to an 
extracellular domain on the amino terminal region of desmoglein 3 where it may 
have a direct effect on the function of desmosomal cadherins79. 
Desmoglein 3 is found in desmosomes. It is detected primarily in the 
lower epidermis, and is expressed more strongly in buccal mucosa and scalp skin 
than in the skin from the trunk. 
Anti desmoglein 1 antibodies are more common in Indian patients. 
Pemphigus Vulgaris sera may also contain auto-antibodies to desmocollins 
and antibodies to cholinergic receptors. 
ANTIBODIES : 
Patients with active disease have antibodies both IgG1 and IgG4 
subclasses,but IgG4 are pathogenic80. Autoantibody production is Tcell 
dependent ; auto reactive  Th 1 and Th 2 cells specific for desmoglein 3 occurs in 
Pemphigus Vulgaris. Antigen-antibody complexes are found on desmosomes in 
early pemphigus lesions. 
COMPLEMENT AND IMFLAMMATORY MEDIATORS: 
Acantholysis can occur without complement but complement enhances 
pathogenicity. Pemphigus antibody fixes components of the complement to the 
surface of epidermal cells81. Antibody binding may activate complement with the 
release of inflammatory mediators and recruitment of activated T cells. 
Complement activation in Pemphigus is increased by interleukin-1α, Tumour 
necrosis factor - α. 
PROTEASES : 
Several Proteases are involved in the pathogenesis of Pemphigus Vulgaris 
of which the important is Plasminogen Activator, which converts Plasminogen to 
plasmin. Plasmin amplifies epidermal damage. 
CLINICAL FEATURES : 
Patients present with oral lesions, in 50-70% cases of Pemphigus Vulgaris. 
They may precede cutaneous lesions or be the only manifestation of the 
disease82. Intact bullae are rare in the mouth. More commonly patients present 
with buccal or palatal erosions. Other mucous surfaces involved include 
conjunctiva, nasal, pharynx, larynx83, esophagus, urethra, vulva, and cervix. 
Cutaneous lesions are vesicles and bullae on apparently normal skin. They 
may be localized or generalized. Sites commonly involved are scalp, face, 
axillae, groins and pressure points. Bullae are initially tense and clear, but 
become flaccid and turbid in two or three days. Itching may be present. 
Nikolsky’s sign: This sign which is elicited by applying lateral pressure with the 
thumb or finger pad on skin over a bony prominence ,results in a shearing 
pressure that dislodge upper layers of epidermis from lower epidermis.84 It can 
be elicited over the normal looking skin of a Pemphigus patient either close to 
the existing lesions (Marginal Nikolsky sign) or over normal looking skin at a 
distant site( Direct Nikolsky sign)  
Bulla  spreading  sign or Lutz sign: Slow unidirectional pressure applied by a 
finger to the bulla cause peripheral extension of bulla beyond the marked margin  
Asboe Hansen sign is a variation of bulla spreading sign it applies to a  smaller, 
intact, tense bulla where the pressure is applied  to the center of the  blister. 
The blisters rupture easily to leave behind painful areas of oozing and 
denuded skin that continue to extend showing little tendency to heal. A 
characteristic offensive odour may emanate from them. They often become 
crusted. The erosions may be assosciated with pain. 
Lesions in skin folds readily form vegetating granulations. Nail dystrophies, 
acute paronychia and subungual haematomas have been observed  
A grading system for pemphigus was devised by Fleischi85 based on the 
no of bulla/erosions.  
LABORATORY FINDINGS :  
1) TZANCK SMEAR :  The base of the blister is gently scraped with a blunt 
scalpel the material obtained spread thinly on a glass slide  
 Tzanck cell is a large rounded cell, with hyperchromatic nucleus, a 
perinuclear halo and peripheral condensation of cytoplasm.   
 
 
 
 
2) SKIN BIOPSY – HISTOPATHOLOGY  
The earliest change consists of intercellular oedema with loss of 
intercellular attachments in the basal layer. Suprabasal epidermal cells separate 
from the basal cells to form clefts and blisters. 
Basal cells remain attached to the basement membrane but separate from 
one another forming ‘Row of Tombstone’ appearance. 
Blister cavity contains acantholytic cells. Blistering is preceded by 
eosinophilic spongiosis in some cases. The superficial dermis has a mixed 
superficial  dermal   inflammatory  infiltrate  which  includes   some  
eosinophils. 86 
1. IMMUNOPATHOLOGY 
Direct Immunoflourescence : 
 IgG deposited on the surface of the Keratinocytes throught out the 
epidermis in and around the lesions. IgG1 and IgG4 are the most common 
subclasses. Complement components (C3), IgM and IgA are present less 
frequently than 1gG. 
 
 
Indirect Immunoflourescence: 
Shows circulating IgG antibodies directed against the cell surface of the 
keratinocytes in 90% of the cases. The best single substrate for the 
demonstration of these antibodies is the monkey esophagus. 
2. IMMUNO ELECTRON MICROSCOPY : 
Deposits of IgG and C3 are localized to the cell membrane. 
3. ELISA 
Detects antidesmoglein3 antibodies in 95% and antidesmoglein 1 antibodies 
in 50% of the cases. 
TREATMENT : 
Topical : 
1. Saline / Potassium permanganate soaks 
2. Topical antiseptics 
3. Topical Steroids 
     Oral lesions : Good oral hygiene 
  Topical or intra lesional steroids 
  Topical ciclosporin mouth wash. 
  
Systemic : 
1. Systemic Steroids 
 Prednisolone  1 – 1.5 mg / kg / day 
2. Immunosuppresive agents 
 Azathioprine  2.5 mg / kg / day 
 Cyclophosphamide  1-3 mg / kg / day 
 Cyclosporin  5 mg / kg / day 
 Methotrexate  10 – 17.5 mg / week 
3. Dexamethasone Cyclophosphamide Pulse therapy 
4. Dexamethasone / Methyl Prednisolone Pulse therapy 
5. Nicotinamide  and Tetracycline 
6. Oral / Intramuscular gold 
7. Mycophenolate mofetil 
8. Plasmapheresis 
9. Intravenous Immunoglobulin 
BULLOUS PEMPHIGOID  
Definition : It is an acquired autoimmune blistering disease of the elderly 
characterized histologically by subepidermal bulla and immunopathologically by 
deposition of antibodies and complement along the epidermal basement 
membrane zone. 
 
 
 
AETIOLOGY : 
Age : Affliction of the elderly 
Sex : More common in males 
Genetics : HLA DQ7 may be associated with Bullous Pemphigoid (only in 
males) 
PATHOGENESIS : 
 The disease is characterized by IgG auto antibodies to hemidesmosome 
associated proteins within the adhesion complex. The auto antibodies have been 
shown to be pathogenic and complement to be necessary for blister formation87. 
ANTIGENS : 
 The two major antigens are BP 230 and BP 180, which are associated with 
hemidesmosomes88.  
 BP 230, also known as BP AG 1 is intracellular and localized to the dense 
plaque. It resides on the short arm of chromosome 6. 
 BP 180, also known as BP AG 2 and collagen XVII is a transmembrane 
molecule with collagenous domains and a long extracellular portion89. The gene 
is situated on chromosome 10. 
 
 
ANTIBODIES : 
 Anti BMZ antibodies are found in the IgG (Predominantly IgG1 and 
1gG4) and occasionally IgA types. 
COMPLEMENT : 
 The deposition of auto antibodies binds C3 along the dermoepidermal 
junction. C5a fragments are thought to stimulate the recruitment of neutrophils to 
the site of inflammation90 
 Autoantibodies bind to BP antigens and activate complement. 
Complement components set off an inflammatory cascade attracting leukocytes, 
degranulating mast cells and releasing inflammatory mediators. The activated 
inflammatory cells release lysosomal enzymes and proteases, cleaving the target 
antigens and disrupting the hemidesmosomes, resulting in blister formation. 
Clinical Features : 
 Commonly starts with itching and a non specific rash. The rash may be 
either urticaria like or occasionally eczematous. Sometimes a figurate erythema 
may precede blister formation. 
 Blisters may arise on erythematosus and on normal skin and may be 
associated with edema. The blisters are tense. They appear mainly on the flexural 
aspects of the limbs and on the central abdomen. Their contents are usually clear 
serous exudates although occasionally this is blood stained. The blisters are tense 
and may remain intact for several days. Erythema may persist at the sites of 
previous blisters for many weeks or months. Milia may be profuse during the 
healing phase. 
 Mucosal lesions occur less frequently and is usually confined to mouth 
Clinical variants : 
Localised : 
a) Pretibial localization 
b) Localised Vulvar Pemphigoid91 
c) Dyshidrosiform Pemphigoid 
Generalised : 
a) Vesicular 
b) Vegetating 
c) Childhood 
d) Pemphigoid nodularis 
e) Lichen Planus pemphigoides 
f) Induced BP 
INVESTIGATIONS : 
1. Peripheral blood eosinophilia 
2. Elevated serum IgE 
3. Tzanck smear: Tzanck cell is not seen. A number of eosinophils are 
present. 
4. Histopathology 
 Blister is subepidermal. The blister may contain numerous eosinophils and 
neutrophils. Biopsies of blisters from erythematous areas show a dermal (a cell 
rich patern)inflammatory infiltrate containing many eosinophils  and neutrophils 
with lymphocytes and histiocytes.  Cell poor pattern is observed when blisters 
develop on relatively normal skin. There is usually a scant perivascular 
lymphocytic inflammation with few eosinophils, some scattered through out 
dermis and some near the epidermis. Eosinophilic spongiosis may be seen. 
4. IMMUNOPATHOLOGY 
Direct Immunoflourescence 
 Best performed on perilesional biopsies. Biopsy will show either IgG and 
C3 (or C3 alone along the Basement membrane zone); deposition of IgA and 
IgM may also occur. 
 
 Indirect immunoflourescence : 
 Can be performed on blood, blister fluid or urine. About 75% have a 
circulating IgG auto antibody to the basement membrane zone. 
5. IMMUNOBLOTTING : 
 Majority of patients have circulating auto antibodies that react with BP 
180 and BP 230 antigens  
6 . ELISA 
Detects circulating auto antibodies to BP 180 
Treatment  
1. Topical / Intra lesional steroids 
2. Systemic Steroids 
3. Immunosuppresants 
Azathioprine  1-2.5mg / kg/ day 
Cyclophosphamide  1-3mg / kg / day 
Low dose methotrexate  5 - 10 mg / week 
Cyclosporine  5 mg / kg / day 
4. Dexamethasone  Cyclophosphamide Pulse therapy 
5. Dapsone 
6. Tetracycline and Nicotinamide 
7. Plasmapheresis 
8. IV Immunoglobulin                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
To study the compliance and complications of Dexamethasone 
Cyclophosphamide Pulse therapy in the management of Immunobullous 
diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS AND MATERIALS 
 This study was done at Government General Hospital, Chennai, during the 
period September 2004 – September 2006. This study included patients with 
Immunobullous diseases (Pemphigus Vulgaris and Bullous Pemphigoid) who 
were selected based on selection and exclusion criteria. 
SELECTION CRITERIA 
1. Patients with moderate to severe disease. 
2. Patients whose disease activity was not controlled with systemic 
steroids and (or) immunosuppresives. 
3. Patients who had completed their family 
4. Patients who were willing to get admitted for the monthly cycles. 
EXCLUSION CRITERIA 
1. Patients with uncontrolled Diabetes Mellitus and Hypertension 
2. Patients with H/o Myocardial infarction or compromised cardiac status. 
3. Patients with hepatic (or) renal impairment 
4. Patients with active Tuberculosis 
5. Elderly > 60 years. 
Details of History and Physical examination were recorded. Diagnosis was based 
on  
a) Clinical features 
b) Tzanck smear 
c) Skin Biopsy 
Informed consent was obtained from all the patients. Weight was 
measured at the time of enrollment and during subsequent admissions.  A 
Grading based on the Fleischi criteria85 was done at the time of first 
admission. 
According to this criteria, the disease is considered 
Severe - When the no. of bullae / erosions exceeds 40. 
Moderate - When the no. of bullae / erosions is between 20 – 40 
Mild - When the no. is less than 20. 
 The number of bullae or erosions were proportional to the percentage of 
the body surface area involved. 
Laboratory evaluation done at the time of enrollment were 
1) Complete haemogram 
  Hb, TC, DC, ESR , Platelet count 
2) Blood Sugar 
3) Blood Urea, Serum  creatinine 
4) Serum electrolytes 
5) Liver function tests 
6) Urine routine 
7) Motion occult blood 
8) Scraping for Candida (if the patients had oral lesions).  
9) Pus culture and sensitivity 
10) Urine culture and sensitivity 
11) Blood grouping and typing 
12) Chest X ray 
13) Mantoux test 
14) ECG, Cardiac evaluation  
15) VDRL 
16) ELISA for HIV 
Ophthalmology and ENT opinion was obtained if necessary. 
 DCP was started only after controlling the infection with systemic 
antibiotics.  If scraping was positive, patients were treated with systemic 
antifungals ( Flucanazole 150mg orally biweekly for one week) 
 The regimen is given in four phases: 
 
 
PHASE 1: 
 Dexamethasone (100mg dissolved in 500ml of 5% Dextrose) was given by 
slow intravenous infusion over 2 hours on 3 consecutive days along with 
Cyclophosphamide infusion 500mg on day 2.  This constitutes one Pulse. These 
Pulses are repeated every 4 weeks.  Between these pulses, patients were given 
50mg cyclophosphamide once a day.  This phase was continued till the patient 
attained remission. 
Remission is defined as: 
a) Disappearance of existing lesions. 
b) Absence of fresh lesions 
PHASE 2: 
 Four weekly pulses of Inj. Dexamethasone and Inj. Cyclophosphamide 
continued along with daily oral Cyclophosphamide for 6 months. 
PHASE 3:  
 Four weekly pulses of Inj. Dexamethasone and Inj. Cyclophosphamide to 
be stopped and patient to receive only 50mg Cyclophosphamide orally daily for 
1 year. 
 
 PHASE 4: 
 All the medications are stopped and the patients are followed up. 
 In this study, Phase 2 was given for 6 months (as followed in the old 
regime) to increase patient compliance. 
 Patients were admitted during each pulse.  Complete haemogram, Blood 
sugar, Renal Function tests, Liver function tests, urine routine, serum electrolytes 
and ECG were repeated before every pulse. Regular monitoring of pulse and 
blood pressure were done during were done during the administration of the 
pulse.  After the completion of each pulse, serum electrolytes and urine for 
RBCs was done.  Chest x ray was repeated after every 6 pulses.    The patients 
were followed for any adverse effects and relapse. 
 In this study, patients were given intermittent steroids depending on the 
severity of the disease.  It was tapered according to the clinical response. 
Vitamin D injection was given after every 3 pulses and oral calcium was 
supplemented during the first two phases.   
The patients were followed for any adverse effects and relapse. 
 
 
 OBSERVATIONS: 
 Twenty One patients with Pemphigus Vulgaris / Bullous Pemphigoid were 
enrolled for this study. 
AGE / SEX DISTRIBUTION : 
AGE (YRS.) MALE FEMALE 
21 – 30 1 6 
31 – 40 0 6 
41 – 50 1 4 
51 – 60 3 0 
 
 Majority of the patients were females (77%). Out of the 21 patients, 5 
were males and 16 were females. 
 Among males, there was 1 each in the age group 21 – 30 yrs and 41 – 50 
yrs, and 3 in the age group 51 – 60 yrs. 
 Out of the 16 females, 6 each were in the age group 21- 30 yrs and  
31 – 40 yrs. 4 females were of the age group 51 – 60 yrs. 
 There was no male in the age group 31 – 40 yrs and no female in the age 
group 51 – 60 yrs. 
 CLINICAL TYPE : 
 
 Male Female 
Pemphigus Vulgaris 1 14 
Bullous Pemphigoid 4 2 
 
 
 15 patients out of the 21 patients had Pemphigus Vulgaris and the 
remaining 6 had Bullous Pemphigoid. Among patients with PV, 14 were females 
and only one was male. There were 4 males and 2 females among patients with 
Bullous Pemphigoid 
 
 
 
 
 
 
 
 
  
 
AGE AND DISEASE DISTRIBUTION: 
 
      AGE (years) 
   Pemphigus 
Vulgaris 
   Bullous 
Pemphigoid 
           21-30                   7                0 
           31-40                   5                 1 
           41-50                   2  2 
           51-60                   0 3 
 
  
Majority of the patients (46.7%) with Pemphigus Vulgaris enrolled for the 
study belong to the age group 21–30 years. 5 patients with Pemphigus Vulgaris 
belonged to the age group 31–40 years and 2 patients belonged to the age group 
41 – 50 years. 
 
 50 % of patients with Bullous Pemphigoid belonged to the age group 51- 
60 years, 1 patient belonged to the age group 31-40 years and 2 patients 
belonged to the age group 41-50 years. 
 
 
GRADING OF SEVERITY 
 
 PV BP 
Mild  0 0 
Moderate 6 2 
Severe 9 4 
  
 
Severity of the disease was graded according to the Fleischi Criteria85. In this 
study, only patients with moderate and severe disease were enrolled. Out of 15 
patients with Pemphigus Vulgaris, 6 had moderate disease while 9 had severe 
disease. 
 4 Patients with Bullous Pemphigoid had severe disease while 2 had 
moderate disease. 
 
 
  
 
Duration of Disease Before Starting DCP. 
DURATION 
(months) 
MALE FEMALE 
0 – 6  2 3 
7 – 12 2 5 
13 – 18 0 5 
19 – 24 1 2 
25 – 30 0 1 
 
The duration of the disease ranged from less than 6 months to 2 ½ yrs.  
 There were 2 males with disease duration ranging from 0 – 6 months and 7 
– 12 months. 1 male had disease duration ranging between 19 – 24 months. 
Among the females, 3 had disease duration less than 6 months. With disease 
duration 7 – 12 months & 13 – 18 months, there was 5 females each ; 2 females 
with duration 19 – 24 months and 1 with duration 25 – 30 months. 
 
 
  
 
DURATION OF INTERMITTENT STERIODS : 
 Out of the 21 patients, 19 patients received intermittent steroids. 2 patients 
with moderate Bullous Pemphigoid did not receive intermittent steroids. 
Intermittent 
Steroids (Months) 
PV BP 
0 0 2 
1 – 3 10 4 
4 – 6 4 0 
7 – 9 1 0 
 
 
 10 patients with Pemphigus Vulgaris and 4 patients with Bullous 
Pemphigoid received intermittent steroids ranging from 1 – 3 months, 4 patients 
with Pemphigus Vulgaris received steroids for 4 – 6 months and 1 patient 
received it for 8 months. The last patient still has not attained complete 
remission. 
 
 
  
 
 
RELATION OF DISEASE DURATION TO NUMBER OF PULSES: 
 
      DISEASE DURATION 
(months) 
 
NUMBER OF 
PULSES 
0-6 4.2 
7-12 5.1 
13-18 5.5 
19-24 7 
25-30 7 
 
 Patients with disease duration of less than 6 months attained remission 
faster,in 4.2 pulses.  Those with disease duration 7-12 months needed 5.1 pulses, 
those with 13-19 months attain remission in 5.5 pulses.  Patients with disease 
duration of more than 18 months took 7 pulses to attain remission  
  
PHASE DISTRIBUTION: 
 
PHASE PV BP 
I 2 0 
II 7 3 
III 6 3 
 
 None of the patients have entered phase IV. 
 Out of the 15 patients with Pemphigus Vulgaris, 2 patients are in Phase I, 
7 patients in Phase II, and 6 patients in phase III. 
 Among the Bullous Pemphigus patients, 3 patients each, are in Phase II 
and Phase III. 
 One patient with Pemphigus Vulgaris was lost to follow up during  
phase II. 
 PATTERNS OF REMISSION : 
I : Moderate disease. May or may not require intermittent steroids. Attains 
remission faster < 6 Pulses. 
II : Moderate disease. Always requires intermittent steroids. Takes > 6 Pulses 
to attain remission 
III : Severe disease. Requires intermittent steroids. Takes less than 6 Pulses to 
attain remission 
IV : Severe disease. Requires intermittent steroids. Takes more than 6 Pulses to 
attain remission 
 2 patients have not attained complete remission. 
 
Pattern of Remission No. of Patients 
I 6 
II 1 
III 8 
IV 4 
 
 COMPLICATIONS : 
IMMEDIATE 
Immediate No. of Patient % 
Palpitations 2 9.4 
Diarrhoea 2 9.4 
Hiccups 1 4.7 
Psychosis 1 4.7 
 
IMMEDIATE : 
1. Palpitations : was noted in 2 patients. One of the patient had Mitral valve 
prolapse. 
2. Diarrhoea : 2 patients developed diarrhea. Diarrhoea occurred within 2 hrs 
after starting the pulse. 
3. Hiccups : Only one patient developed hiccups which started immediately 
on administering the pulse.  
Psychosis : 1 patient who was emotionally stable before the pulse 
developed irrelevant talk on starting the pulse 
 DELAYED : 
 No. of Patients % Appearance 
Average Pulses 
Menstrual 
irregularities 
4 26.6(F) 3.6 
Weakness 5 23.5 2.5 
Rise in Fasting 
Blood Sugar 
3 13.1 6.5 
Arthralgia 3 13.1 5 
Infections 3 13.1 2.3 
Hair loss 3 13.1 3.6 
Headache 2 9.4 3 
Taste loss 2 9.4 3.5 
Weight gain 2 9.4 1.2 
Avascular 
Necrosis 
2 9.4 8.5 
Increase in BP 2 9.4 3.5 
Sleep 
disturbances 
1 4.7 3 
Striae 1 4.7 5 
Blurring of vision 1 4.7 6 
 
 
 
DELAYED : 
1.  Menstrual Irregularities : 
 2 patients developed amenorrhoea while other 2 developed decreased 
menstrual flow. These irregulauties were noted after an average of 3.6 pulses. 
This was the most common complication noted in this study. 
2. Weakness : 
 This was one of the most common complication noted after administring 
pulse therapy. This was observed in 5 patients who developed it after an average 
of 2.5 pulses. 
3. Rise in fasting Blood sugar 
 3 patients, including 1 known diabetic (who was on meal plan) had a rise 
in blood sugar level after an average of 6.5 pulses. 
4. Arthralgia : 
 3 patients complained of vague pains and discomfort over the knee, ankle, 
hip joints after an average of 5 pulses. One patients also have severe back pain. 
5. Infection : 
 3 patients developed infections after an average of 2.3 cycles. 
 
6. Hair loss : 
 3 Patients noted reversible loss of hair after an average of 3.6 cycles. 
7. Headache : 
 2 patients developed headache after an average of 3 cycles which was not 
related to any time of the day. 
8. Loss of taste : 
 2 patients had partial loss of taste sensation after an average of 3.5 cycles. 
9. Weight gain :  
 Weight gain (Significant) was noted in 2 patients. They had a weight gain 
of >10% of body weight. 
10.     Avascular Necrosis  of head of femur:  
  2 patients developed avascular necrosis after an average of 8.5 pulses. One 
of the patient had completed phase II.   
11. Rise in BP 
 2 patients developed significant rise in BP after an average of 3.5 pulses. 
12. Sleep Disturbance : 
 1 patient developed difficulty in initiation of sleep, after 3 pulses. 
 
13. Striae :   
 Only one patient developed striae after 5 pulses. 
14. Blurring of vision : 
 1 Patient developed blurring of vision after 6 pulses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
The study included 21 patients with moderate to severe immunobullous 
disease (Pemphigus Vulgaris and Bullous Pemphigoid). 
Majority (77%) enrolled for the study were females.  Mean age group for 
Pemphigus was 32.06 years and for Bullous Pemhigoid was 49 years mean age 
for Pemphigus vulgaris  and Bullous pemphigoid corresponds to that given in 
literature 73. 
In the study done by Sachidanand et al53, Pemphigus vulgaris, Pemphigus 
foliaceus, Bullous Pemphigoid, Dermatitis herpetiformis were included. This 
study only included patients with Pemphigus vulgaris and Bullous pemphigoid. 
Intermittent steroids were given in between the pulses in the dose of 15-
20mg to achieve a faster remission. Phase I was considered completed only 
when the patients did not require steroid supplementation and were free of the 
lesions between the pulses.  In the study, it was given in 90.5% of the cases 
when compatred to the study by Lakshmi et al28, where it was given in 45%.  It 
was given for an average of 2.9 months. 
     Scalp and oral lesions were the last to respond and heal, in most of the 
patients as in the study by Lakshmi et al28. 
In the study, 19 patients (90.5%) attained complete remission.  In 
the study by Sachidanand, 82%53 attained complete remission.  Among the 
2 patients who attained compete remission, one patient has completed 9 
pusles and the other patient has received only 3 pulses. The average 
pulses given  to attain complete remission in this study was 5.4 pulses,  as 
compared to the study by vikram et al31 where the average was 6.5 pulses.  
In the study done by Sachidanand et al53, 70% attained  remission by the 
3rd pulse, and in the study by Rao et al28, it took an average of  8 pulses to 
attain complete remission. 
Patterns of remission: 
 In the study, 4 patterns of remission were noted.  
I. Moderate disease85, may or may not require intermittent steroids, attained    
remission in less than 6 months. 
II. Moderate disease,  required intermittent steroids, attained remission in 
 more than 6 pulses. 
III. Severe disease85, required intermittent steroids, attained remission in less 
than 6 pulses. 
IV.Severe disease, required intermittent steroids, attained remission in 
more than 6 pulses.   
This study was different from the patterns observed by Kanwar & Kaur29  
in that mild cases were not included and there was no cases of relapse. 
PHASE: 
 The maximum number of patients are in Phase 2 (47.6%).  None of the 
patients have reached Phase 4 due to the short duration of the study.  The 
percentage of patients in Phase 1 is 9.5% and that in Phase 3 is 42.8%. 
COMPLICATIONS: 
Immediate: The immediate complications noted in our study were    Palpitations 
9.4%, Diarrhoea 9.4%, Hiccups 4.7%, Psychosis 4.7%.  In the study by Bushan 
kumar and Rajesh Jain34, the immediate complications were Palpitations 7.5%, 
Hiccups 6.1% and Psychiosis 3.6%. 
 Palpitations noted in the two patients subsided without any treatment.  
ECG taken immediately after the pulse showed only sinus tachycardia.  Hiccups 
occurred at the rate of 5-6 per minute, which stopped completely within 24 
hours.  It was treated with Inj. Ondensetron.  The patient who developed 
psychosis was given a short course of tricyclic antidepressants for 2 months.  She 
did not develop psychosis during the subsequent pulses. 
Delayed:  The common delayed complications noted in our study were menstrual 
irregularities (26.6%), and weakness (23.5%).  
 These were the common complication noted by Bushan Kumar in this study34.   
 Menstrual irregularities manifest as amenorrhoea or decrease in menstrual 
flow.  Both the patients with amenorrhoea regained their menstrual flow 
spontaneously.  Weakness, which manifested as lethargy, developed mainly in 
patients who were more than 40 years old.  In three of the five patients, return to 
normalcy occured with the start of the phase 3. 
 Rise in fasting blood sugar occurred in 13.1% compared to 18% in the 
above  study34.  One of trhe patient was a diabeteic who was already on Inj. 
Insulin.  With the increase in dosage of insulin levels, blood sugar levels 
returned to normal. 
 Arthralgia, which manifested as vague pains in the knee joint, ankle point, 
was noted in 13.1%, which was the same as that noted in the above study.  
Analgesics were given if the pain was severe.  
 Hairloss, was noted in 13.1%.   The hair loss was diffuse which recovered 
partially during continuation of the pulses.  
Infections noted in the study by Rao et al28, were bacterial infections, viral ( 
reactivation of herpes zoster), and fungal infections.  In this study the infctions 
noted were vaginal candidaisis and urinary tract infction (one of the patient who 
developed infection was a diabetic). Rise in blood pressure was noted in 2 
patients. They had normal blood pressure at the time of enrolment.  This 
complication was noted in the study by Vikram et al31 
Avascular necrosis of head of femur was noted in 9.4%.  This 
complication was noted in the study by Rao et al28.  The higher percentage of 
this complication in our study could be attributed to the longer duration of 
intermittent steroids in one patient, and to the history of trauma to the hip in 
another patient.  Both the patients were in Phase II, when the complicatrion 
developed.  They are maintened on analgesics and rest. 
 The other complications noted were infections ( 13.1%),Headache (9.4%), 
loss of taste sensation (9.4%), weight gain (9.4%), increase in blood pressure 
(9.4%), and striae (4.7%). 
 The head ache was diffuse and not related to any time of the day. It 
resolved within 2 or 3 days of the pulse.  One patient had difficulty in initiation 
of sleep. 
 Weight gain was noted in 2 of the patients. Many of the patients developed 
weight gain during the period they received intermittent steroids, but after 
intermittent steroids were stopped, the weight returned to that at the time of 
enrollment. 
  
CONCLUSION 
 
The results of the study indicate a high degree of positive outcome  
among patients diagnosed with immunobullous disease(Pemphigus vulgaris 
and Bullous Pemphigoid)   
1) Clinical remission was achieved in 90.5% of the patients. 
2) The time taken to attain complete remission was 5.7 pulses. 
3) The response did not show much correlation with the severity of the  
disease. 
4) There appeared to be correlation between the response and the duration  
    of the disease at the initiation of therapy. 
5) Patients with Bullous pemphigoid (irrespective of the severity and  
duration of disease) showed a faster response than Pemphigus vulgaris. 
6) The  common complications noted were menstrual irregularities and  
weakness.  The other side effects noted in order of priority were  
arthragia, infections, rise in fasting blood sugar, palpitations, diarrhoea, 
head ache, taste loss, weight gain,avascular necrosis, increase in blood 
pressure, hiccups, psychosis, sleep disturbances, blurring of vision, stria.  The 
serious complication noted was avascular necrosis of head of femur. 
7) There was no cases of relapse or mortality associated with the therapy. 
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INDEX  TO MASTER CHART 
 
 
DUR : Duration (Months)  
S : Skin Lesions 
MM : Mucous Membrane Lesions 
ST : Steroids  
C : Cytotoxic Drugs 
V : Vesicle  
B : Bulla  
P : Pustule  
E : Erosion 
O : Oral  
C : Conjunctival  
G : Genital 
N/E : Normal/Erythematous Skin 
T/F : Tense/Flaccid 
NS : Nikolsky Sign 
D : Direct NS 
M : Marginal NS 
BSS : Bulla Spreading Sign 
GR : Grading 
MO : Moderate Grade 
SE : Severe Grade 
TZ : Tzanck Smear 
HPE : Histopathological Examination 
PV : Pemphigus Vulgaris 
BP : Bullous Pemphigoid 
IS : Intermittent Steroids 
PI : Phase I 
PII : Phase II 
PIII : Phase III 
 AI : Area of Involvement  
PR : Pattern of Remission 
IC : Immediate complication 
DC : Delayed Complication 
Pa : Palpitation 
H : Hiccup 
Di : Diarrhoea 
Ps : Psychosis 
Mi : Menstrual irregularities 
Rs : Rise in Fasting Blood Sugar 
H : Headache 
Sl : Sleep Disturbance 
Ar : Arthralgia 
Bv : Blurring of Vision 
Hl : Hair Loss  
Ts : Loss of Taste 
Wg : Weight Gain 
A : Avascular Necrosis 
RB : Rise In Blood Pressure 
St : Striae 
In : Infection 
W : Weakness 
 
 
 
 
  
 
 
 
PROFORMA 
 
NAME :    AGE:   SEX: 
 
OCCUPATION:    IP.NO: 
 
ADDRESS: 
 
COMPLAINTS: Skin Lesions : Duration 
   Oral Lesions : Duration 
 
HPI: Blistering Skin Lesions : Duration  
 Blisters Over Normal/Erythematous skin  
 Ruptures immediately/after 2-3 days  
 H/O Pruritis 
 H/O Oral Lesions  : Duration  
 H/O Difficulty in swallowing  
 H/O Hoarsenses of voice  
 H/O Discharge/watering of eyes 
 H/O Burning micturition  
 H/O Loss of Weight/Apetite  
 H/O Drug Intake  
 
Treatment H/O: 
 
Diet H/O  : 
 
Past H/O :  H/O Diabetes Mellitus/Hypertension/Tuberculosis/Myocardial 
Infection/Liver or kidney disease 
 
Personal H/O: Married/Unmarried  
 
   No of Children  
 
   H/O Sterlisation  
 
Menstrual H/O: Cycles  
   Regular/Not 
 
Family H/O : Similar H/O among family members  
 
 
 
 
 
 
 
GENERAL EXAMINATION: 
 
¾ FEBRILE  
¾ ANAEMIC 
¾ JAUNDICE  
¾ GEN LYMPHADENOPATHY  
¾ PEDAL EDEMA  
 
 
WEIGHT:   PULSE:   BP:  
 
SYSTEMIC EXAMINATION :  
 
CVS     : 
 
RS     : 
 
P/A     : 
 
D/E     :  
 
SKIN LESIONS :  
 
 Vesicles/Bulla/Pustules/Erosion 
 
 Vesicles / Bulla : Distribution 
     Over normal or erythematous skin 
     Tense or Flaccid 
     Clear or haemorrhagic 
     Nikolsky Sign: Direct or marginal  
Bulla spreading Sign  
Area of Involvement  : 
 
Post inflammatory Hypopigmentation or hyperpigmentation 
 
Oral Lesions  : 
Ocular Lesions :  
Genitalia   :  
Scalp    : 
Palms, Soles  : 
Nails   : 
Hair   : 
INVESTIGATIONS: 
 
 Tzanck  
 
 Histopathological Examination  
 
 Complete Hemogram 
 
 Blood Sugar 
 
 Renal Function Test  
 
 Serum Electrolytes 
 
 Liver Function Test  
 
 Urine – Routine 
 
 Motion – Occult Blood  
 
 ECG 
 
 Chest X-ray 
 
 Mantoux Test 
 
 Pus C & S 
 
 Urine C & S 
 
 VDRL  
 
 ELISA for HIV 
 
 Scraping for Candida  
 
 
 
 
 
 
 
 
 
 
 
 
COMPLICATIONS:  
 
 
 
COMPLICATIONS 
 
 
PHASE I 
 
PHASE II 
 
PHASE III 
 
 
 
IMMEDIATE 
   
 
 
 
 
 
 
 
 
 
DELAYED 
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